Joseph A. November is an Associate Professor in the Department of History at the University of South Carolina, affiliated with the McCausland College of Arts and Sciences. His research focuses on the history of biomedical computing, distributed computing, and the intersection of technology and medicine. He holds a Ph.D. from Princeton University (2006), an M.A. from the University of Chicago (2002), and a B.A. from Hamilton College (1997). His work includes the award-winning book Biomedical Computing: Digitizing Life in the United States (2012), which explores the co-development of biomedicine and computing technologies. Current projects include Revolutions@home , examining distributed computing in protein folding research, and a biography of computing pioneer Robert S. Ledley. He has received grants from the NSF, NIH, and the Charles Babbage Institute. Teaching interests span the history of science and technology, including courses on the history of medicine, digital humanities, and the role of games in historical education. He actively contributes to professional organizations like SHOT and the History of Science Society. Awards include the Computer History Museum Prize (2013) and the National Institutes of Health DeWitt Stetten Fellowship (2007-2008). His research bridges historical analysis with contemporary issues in technology and biomedical ethics.
Herman Barkema is a Professor in Epidemiology of Infectious Diseases at the Faculty of Veterinary Medicine, University of Calgary, with a joint appointment in the Department of Community Health Sciences, Cumming School of Medicine. His research focuses on preventing infectious diseases in cattle herds (e.g., mastitis, Johne’s disease) and antimicrobial resistance, integrating animal and public health perspectives under the One Health framework. He founded the Department of Production Animal Health and leads the AMR – One Health Consortium and CAN-AMR-Net. DVM, Veterinary Medicine, Utrecht University (1988) PhD, Veterinary Science, Utrecht University (1998) His work spans clinical veterinary epidemiology, antimicrobial resistance mechanisms, and zoonotic disease control. He has over 425 publications and collaborates globally, including as a Foreign Expert at China Agricultural University. Recent research trends highlight his focus on multi-omics approaches, ceRNA networks, and antimicrobial stewardship in dairy systems, with significant contributions to Johne’s disease diagnostics and mastitis prevention. Roger Morris ISVEE Award (2024) Plowright Prize (2022) Killam Annual Professorship (2019) Multiple Journal of Dairy Science Most Cited Awards (2011–2024) Fellow, Canadian Academy of Health Sciences (2014) Dr. Barkema supervises graduate students and postdoctoral fellows, emphasizing interdisciplinary mentorship. He co-developed the Veterinary DialogueTrainer for clinical communication training and participates in public engagement initiatives like Breakfast on the Farm. He leads the AMR – One Health Consortium and CAN-AMR-Net, integrating stakeholders across Canada and internationally. His affiliations include the Snyder Institute for Chronic Diseases and strategic initiatives on Infectious Diseases and One Health (2015–2025).
Swiss Federal Institute of Technology in LausanneSwitzerland
Didier Trono is a Full Professor at École Polytechnique Fédérale de Lausanne (EPFL), where he leads the Laboratory of Virology and Genetics (LVG) within the School of Life Sciences. Formerly, from 2004 to 2012, he served as the founding dean of EPFL's Faculty of Life Sciences, orchestrating its development and growth during this formative period. Trono received his medical education at the University of Geneva, followed by clinical training in pathology, internal medicine, and infectious diseases in Geneva and at Massachusetts General Hospital in Boston. His scientific career began at the Whitehead Institute of MIT, and in 1990 he was recruited by the Salk Institute of San Diego to launch an AIDS research center. After seven years in the United States, he returned to Europe and eventually joined EPFL. Dr. Trono's research has evolved significantly over his career. Initially focusing on virus-host interactions, he studied pathogens like HIV and Hepatitis B virus, creating HIV-derived genetic transfer tools that are now successfully used in gene therapy. For approximately the last fifteen years, his research has centered on epigenetics, particularly exploring the impact of retroelements and their control mechanisms on development and physiology of higher organisms, including humans. His laboratory investigates how transposable elements and KRAB zinc finger proteins regulate gene expression, with important implications for understanding cancer biology and developing new diagnostic and therapeutic approaches. Analysis of his recent publications (2022-2024) reveals a strong focus on transposable elements, KRAB zinc finger proteins, and their roles in gene regulation and cancer. His work combines molecular biology, genomics, and bioinformatics approaches to understand how these ancient viral remnants have been co-opted by the host genome to regulate development and cellular functions. The research spans basic molecular mechanisms to potential clinical applications in cancer diagnosis and therapy, with some recent work also addressing SARS-CoV-2 and immune responses. Throughout his career, Professor Trono has mentored numerous PhD students, including Bojkowska Karolina, Brandão Sanches Vong Martins Filipe Amândio, Bulliard Yannick, Coluccio Andrea, Corsinotti Andrea, Coudray Alexandre, De Tribolet-Hardy Jonas Caspar, and Dorschel Iris Arianna. His laboratory has received significant funding to support research at the intersection of virology, genetics, and epigenetics, contributing to EPFL's reputation as a leading institution in life sciences research. The Trono Laboratory continues to be at the forefront of research on retroelements and their regulatory mechanisms, maintaining a vibrant research environment that bridges fundamental biological questions with potential medical applications, particularly in cancer research and precision medicine.
Harris H. Wang is an Associate Professor in the Department of Systems Biology and Department of Pathology and Cell Biology at Columbia University's Vagelos College of Physicians and Surgeons, where he also serves as Interim Chair of Systems Biology. He is affiliated with the Center for Computational Biology and Bioinformatics (C2B2) and the Integrated Program in Cellular, Molecular and Biomedical Studies (CMBS). B.S., Physics and Mathematics, MIT Ph.D., Biophysics, Harvard University Dr. Wang's research lies at the intersection of systems and synthetic biology, focusing on developing foundational technologies for genome engineering, microbiome manipulation, and synthetic genomics. His lab pioneers methods such as MAGE, MAGIC, CAST, and CAMII to enable high-throughput genetic manipulation, in situ microbiome engineering, and AI-driven microbial culturomics. Key research themes include understanding microbial community dynamics, engineering cellular memory systems, designing biocontained genetic circuits, and applying synthetic biology to human health challenges in personalized medicine and infectious disease. His recent publications reveal a strong trend in spatial and functional metagenomics, CRISPR-based microbiome editing, and synthetic biology tools for data storage and genetic stability. The articles span high-impact journals like Nature , Science , and Nature Biotechnology , reflecting his leadership in developing scalable, programmable biological systems. Scientific Awards: NIH Director’s Early Independence Award Forbes 30 Under 30 in Science Sloan Research Fellowship NSF CAREER Award ONR Young Investigator Award Burroughs Wellcome Fund PATH Award Schaefer Scholar Blavatnik National Award Vilcek Prize PECASE Dr. Wang has advised numerous PhD and postdoctoral researchers, many of whom have gone on to independent scientific careers. His lab is supported by major grants from NIH, NSF, DARPA, DOE, and foundations including the Bill & Melinda Gates Foundation and CZ Biohub NY. He is actively involved in educational initiatives, including organizing Columbia’s iGEM team and the Cold Spring Harbor Laboratory Synthetic Biology course. The Wang Lab is based at the Columbia University Irving Medical Center and is part of national consortia such as the Engineering Biology Research Consortium (EBRC) and the Genome Project-Write (GP-Write) initiative. The lab develops and applies cutting-edge technologies in automation, machine learning, and synthetic biology to engineer microbiomes for applications in medicine, global health, and climate change.
Dr. Camila Aquino serves as Assistant Professor in both the Department of Clinical Neurosciences and Department of Community Health Sciences at the University of Calgary's Cumming School of Medicine, and is a Full Member of the Hotchkiss Brain Institute. As Medical Director of the Deep Brain Stimulation Program, she specializes in Parkinson's disease, essential tremor, dystonia, and chorea management, including EMG-guided botulinum toxin injections. Her educational background includes: M.D. in Medicine from Escola Superior de Ciencias da Santa Casa (2005) M.S. in Neurosciences from Federal University of Sao Paulo (2012) Ph.D. in Neurosciences from Federal University of Sao Paulo (2019) M.S. in Health Research Methods, Clinical Epidemiology from McMaster University (2020) Dr. Aquino's research addresses unmet needs in movement disorders through innovative clinical trial designs for Parkinson's disease, focusing on precision-medicine approaches, early intervention, and outcome optimization. She actively evaluates neuromodulation therapies including Deep Brain Stimulation, Spinal Cord Stimulation, and MRgFUS, with emphasis on expanding indications and improving patient outcomes. As an International Parkinson and Movement Disorder Society member, she chairs the web-based learning committee and serves on evidence-based medicine and outcome measure committees. Analysis of her 15 most recent publications (2021-2025) reveals a cohesive research trajectory centered on Parkinson's disease management, with dominant themes in motor fluctuation treatments, deep brain stimulation methodology, and clinical trial innovation. Her work bridges fundamental clinical practice guidelines with advanced neuromodulation technologies, demonstrating consistent commitment to evidence-based solutions for movement disorders. Her scientific recognition includes: Parkinson Canada research grant Mohammed Al Zaibak Foundation scholarship CAPES scholarship from Brazilian Ministry of Education Dr. Aquino has secured significant research funding supporting clinical trials in Parkinson's disease neuroprotection and neuromodulation therapies. While specific student advisees aren't listed, her leadership of the DBS Program and active clinical trial portfolio indicate substantial mentorship responsibilities. Her grant portfolio emphasizes translational research with direct clinical impact. She directs the University of Calgary's Deep Brain Stimulation Program and contributes to the MRI-guided focused ultrasound initiative. Through her International Parkinson and Movement Disorder Society committee roles, she shapes global educational standards and evidence-based practices in movement disorders.
Ole Winther is Professor in High dimensional biological data analysis/Machine learning at the Department of Biology, University of Copenhagen and Professor in Data science and complexity at DTU Compute, Technical University of Denmark. He serves as CRO and co-founder of raffle.ai, CTO and co-founder of FindZebra, Head of ELLIS Unit Copenhagen, and co-PI of the Machine Learning for Life Science Center. His research spans Bioinformatics , Machine Learning , and AI for Science , focusing on applying deep learning to biological sequence analysis, latent variable models, and medical NLP. Winther's work develops predictive and generative models for bioinformatics, with significant contributions to protein localization tools (SignalP, DeepLoc, DeepTMHMM), single-cell genomics, and novel deep learning architectures like variational autoencoders and diffusion models. Analysis of Winther's recent publications (2023-2025) reveals a strong trend toward integrating protein language models with traditional bioinformatics approaches and applying diffusion models to scientific problems. His work bridges theoretical machine learning advancements with practical applications in biology and medicine, particularly in protein sequence analysis, medical search engines, and scientific simulation acceleration. Winther currently supervises a diverse research group including Panagiotis Antoniadis, Rachael M. DeVries, Jun Wang, Beatrix M. G. Nielsen, Felix G. Teufel, Irene R. Rodriguez, Anders Christensen, and Christopher Heje Grønbech. His former students have established successful careers at institutions including Google, Apple, and various startups, with notable alumni like Casper Sønderby (Google Brain) and Søren Sønderby (Apple). He leads significant research initiatives including the ELLIS Unit Copenhagen and the Machine Learning for Life Science Center, while maintaining active industry partnerships through his co-founded companies raffle.ai (enterprise search using NLP) and FindZebra (search engine for rare diseases). His teaching includes Deep Learning courses at both DTU (02456) and University of Copenhagen (NDAK24002U).
Professor Maria Craig is a distinguished academic and researcher at the University of New South Wales, Faculty of Medicine & Health, specializing in childhood diabetes research. She holds a prominent position as a Professor with extensive contributions to the field of pediatric endocrinology and diabetes, particularly focusing on type 1 diabetes in children. Professor Craig's educational background includes: MB BS from the University of Melbourne MMedSc(ClinEpid) from the University of Newcastle PhD from the University of Sydney FRACP (Fellow of the Royal Australasian College of Physicians) Professor Craig's research primarily focuses on childhood diabetes, with special emphasis on prediction and prevention of type 1 diabetes. She has a significant interest in the association between viruses and type 1 diabetes, collaborating with the Virology Research Group at Prince of Wales Hospital (POWH). Together with Professor Bill Rawlinson, she leads the viral theme for the multicentre ENDIA study (endia.org.au). As principal investigator for the CoRD trial, she is conducting a world-first phase 1 study using autologous cord blood for prevention of type 1 diabetes in children with islet autoimmunity. Additionally, she serves as principal investigator for the Australasian Diabetes Data Network (ADDN). Her research portfolio also encompasses the epidemiology of various forms of childhood diabetes (type 1, type 2, cystic fibrosis related diabetes and monogenic diabetes) and diabetes complications, in collaboration with Professor Kim Donaghue at the Children's Hospital at Westmead. Professor Craig's extensive publication record, including over 361 journal articles, demonstrates her leadership in advancing our understanding of childhood diabetes. Her recent work shows increasing focus on early detection methods, risk prediction models, technological interventions for diabetes management, and the complex interplay between viral infections and autoimmune diabetes development. She has been instrumental in developing clinical practice guidelines through her role as co-editor of the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines. Professor Craig has received numerous prestigious awards recognizing her contributions to pediatric endocrinology and diabetes research: Australian Paediatric Endocrine Group Young Investigator's Award (1997) Asia Pacific Paediatric Endocrine Society Clinical Teaching Award (2008) Lifetime Honorary Member, Caring and Living as Neighbours (2013) Australian Diabetes Society Jeff Flack Diabetes Data Award (2019) Australian Paediatric Endocrine Group Norman Wettenhall Award for Research and Innovation (2019) Throughout her career, Professor Craig has demonstrated exceptional leadership in professional societies, having served as former president/treasurer of the Australasian Paediatric Endocrine Group (APEG) and currently as Scientific Convenor of the Asia Pacific Paediatric Endocrine Society Fellows school. Her work with the ENDIA study and Australasian Diabetes Data Network represents significant collaborative research efforts involving multiple institutions across Australia and internationally. Her principal investigator roles for major studies indicate substantial research funding support. Professor Craig leads several important research initiatives including the ENDIA study, the CoRD trial, and the Australasian Diabetes Data Network. These programs involve multidisciplinary teams of researchers, clinicians, and support staff working collaboratively to advance understanding and treatment of childhood diabetes. Her work at the intersection of virology and diabetes represents a unique and innovative approach to understanding the environmental triggers of type 1 diabetes.
Hauke Smidt is a Personal Professor at Wageningen University & Research, affiliated with the Molecular Ecology group within the Faculty of Veterinary Medicine and Animal Sciences. His research focuses on microbial ecology, particularly gut microbiota dynamics, antibiotic resistance, environmental microbiology, and the One Health framework. Smidt has supervised over 50 PhD students and contributed to 519 publications, including studies on microbiome resilience, fermented food impacts, and bioremediation strategies. Education and affiliations include leadership roles in projects addressing antimicrobial resistance, pig health, and drinking water microbiology. His work spans collaborations across Europe and Asia, with notable contributions to understanding microbial community responses to environmental stressors and dietary interventions. Smidt is actively involved in public outreach, as seen in media contributions discussing microbiome research and health benefits. Key projects include aquifer treatment for drinking water, microbiome simulation models, and combating plant pathogens. His awards and recognition are not explicitly listed, but his extensive publication record and project leadership highlight significant academic impact.
Dr. Keith Alexander Sharkey is a Professor in the Department of Physiology and Pharmacology at the Cumming School of Medicine, University of Calgary. He is also a Full Member of both the Hotchkiss Brain Institute and The Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases. Dr. Sharkey has been at the University of Calgary since his appointment as Assistant Professor in 1990, dedicating his career to understanding the neural control of the gastrointestinal tract. From 2005-2021, he held the Crohn's and Colitis Canada Chair in Inflammatory Bowel Disease Research, demonstrating his longstanding commitment to advancing knowledge in gastrointestinal sciences. Dr. Sharkey's educational journey began with a BSc (Hons) in Nutrition from the University of London in 1981, followed by a PhD in Physiology from the University of Liverpool in 1985. After completing postdoctoral training in Hungary, the UK, and Canada, he joined the University of Calgary faculty in 1990, where he has remained throughout his distinguished academic career. Dr. Sharkey's research program centers on understanding the physiology and pathophysiology of the neural control of the gastrointestinal tract and brain-gut interactions in health and disease. His laboratory investigates two main areas: the role of the endocannabinoid system in regulating GI motility and intestinal barrier function, and the physiology of the enteric nervous system in controlling motility and barrier function. His work employs state-of-the-art approaches including live cell imaging and molecular genetics. Recent publications show his expanding interest in connections between gut function and neurodegenerative conditions like ALS, with multiple 2024-2025 papers examining sexual dimorphism in disease processes and gut-brain axis mechanisms. Fellow, Royal Society of Canada (2024) Cumming School of Medicine's van de Sande Distinguished Achievement Award for Mentorship (2021) Distinguished Research Award, American Physiological Society (2021) Finkelstein Award for Excellence, Crohn's and Colitis Canada (2016) Fellow, Canadian Academy of Health Sciences (2015) Fellow, Canadian Association of Gastroenterology (2015) Killam Annual Professor Award, University of Calgary (2013) Dr. Sharkey has mentored numerous students throughout his career, as evidenced by his 2021 Mentorship Award. His research is supported by significant funding, including a CIHR Foundation grant exploring how enteric nerves and glia maintain intestinal homeostasis. He has also participated in university strategic initiatives focused on Brain and Mental Health (2015-2021) and Infections, Inflammations and Chronic Diseases (2015-2021), demonstrating his interdisciplinary approach. The Sharkey Lab provides a safe, inclusive, and diverse research environment that encourages open scientific exchange from diverse viewpoints. His laboratory is actively engaged in multiple collaborative projects, including investigations with UBC Okanagan on diet and probiotics targeting the gut-brain metabolic interactome, and with University of Calgary colleagues studying gut microbiota's role in ALS. Dr. Sharkey continues to advance our understanding of neural mechanisms controlling gastrointestinal function with upcoming courses scheduled for Fall 2024 and Winter 2025.
Romain Lopez is an Assistant Professor of Computer Science and Biology at New York University, with a joint appointment in the Courant Institute of Mathematical Sciences and the Department of Biology. He will be joining NYU in September 2025, bringing expertise at the intersection of machine learning and computational biology. Prior to joining NYU, he was a Postdoctoral Fellow at Genentech and Stanford Medicine from 2021 to 2025, working with Jonathan Pritchard and Aviv Regev. Dr. Lopez received his educational training at prestigious institutions: PhD in Computer Science (2021) from the University of California, Berkeley, advised by Mike Jordan and Nir Yosef M.S. in Applied Mathematics (2016) from École polytechnique, Palaiseau, France Dr. Lopez's research focuses on developing machine learning methods to understand biological systems at the cellular level. His work bridges computational techniques with biological applications, particularly in single-cell and spatial omics analysis. He pioneered probabilistic approaches for single-cell analysis with scVI and co-developed scvi-tools, now widely adopted tools in the field. His research spans deep generative models, causal inference, perturbation modeling, and representation learning for biological data. His publication record demonstrates a consistent trajectory of innovation in computational biology, with recent work focusing on spatial biology, disentangled representations of cellular perturbations, and causal modeling of cellular responses. He has made significant contributions to the field of single-cell analysis, developing methods that help scientists interpret complex cellular data and predict how cells respond to various perturbations. Dr. Lopez has received numerous honors and awards for his research: Best Paper Award from the ICML Workshop on AI for Science (2024) Best Paper Award Honorable Mention from the AAAI Conference on Artificial Intelligence (2021) Best Student Poster Award from the ICML Workshop on Computational Biology (2019) UC Berkeley EECS Departmental Graduate Fellowship (2016) Carnot Foundation Fellowship (2016) Monahan Foundation Fellowship (2016) French National Defence Medal, Bronze Echelon (2014) At NYU, Dr. Lopez will lead the Biological Machine Learning group, which develops probabilistic machine learning methods to uncover biological mechanisms governing cellular behavior and disease. His lab focuses on creating tools that transform complex cellular data into biological insights, with applications in understanding cancer, immune responses, and fundamental cellular processes. His work has significant implications for precision medicine and drug discovery.
University of Illinois Urbana-ChampaignUnited States
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
Sriram Subramaniam is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia (UBC) and holds the Gobind Khorana Canada Excellence Research Chair in Precision Cancer Drug Design. His research leverages cryo-electron microscopy (cryo-EM) to advance structural biology and drug design, focusing on protein dynamics and therapeutic target identification. Education: PhD in Physical Chemistry (1987) from Stanford University; MSc in Chemistry (1981) from Indian Institute of Technology, Kanpur. Subramaniam's interdisciplinary work combines cryo-EM with computational tools and molecular biology to study protein structures at atomic resolution. His lab has pioneered cryo-EM applications in precision medicine, including mapping small molecule drugs on patient-specific cancer mutants. Recent publications (2024-2022) highlight his contributions to understanding SARS-CoV-2 immune evasion, structural mechanisms of ATPases, and AI integration in structural biology. His research spans viral entry mechanisms, CRISPR systems, and neurodegenerative disease pathways. Scientific Awards: Gobind Khorana Canada Excellence Research Chair NIH Director’s Award for Scientific Excellence Fellow of the Biophysical Society Breakthrough Prize nomination Based at the Djavad Mowafaghian Center for Brain Health, Subramaniam leads the Program in Cryo-EM Guided Drug Design, contributing to over 177 peer-reviewed publications with a career h-index of 58 and citations exceeding 12,340.
John Oakey is a Professor and Graduate Coordinator in the Department of Chemical and Biomedical Engineering at the University of Wyoming, with additional affiliations to the INBRE Program, Molecular and Cellular Life Sciences Program, and Materials Science and Engineering Program. Education Postdoctoral Fellow, Center for Engineering in Medicine, Massachusetts General Hospital & Harvard Medical School (2007–2010) Ph.D. Chemical Engineering, Colorado School of Mines (2003) M.S. Chemical Engineering, Colorado School of Mines (1999) B.S. Chemical Engineering, Penn State University (1997) Research Interests Oakey’s laboratory integrates fluid dynamics, colloidal science and materials science to understand how biological systems behave under flow, on surfaces and within complex 3-D geometries. A unifying theme is the use of microfabrication and microfluidics to create new diagnostic, prognostic and therapeutic platforms. Current thrusts include: Heterogeneous biomaterials: self-assembled particulate tissue scaffolds whose mechanical and transport properties can be temporally programmed. Inertial microfluidics: exploiting lift forces for membrane-free particle sorting, enrichment and diagnostics. Multi-temporal analysis by flow cytometry: development of closed-loop, high-throughput microfluidic cytometers for longitudinal single-cell studies. Publication Trends From 2025 back to 2010, Oakey’s articles reveal a consistent trajectory that marries fundamental physics (microtubule mechanics, inertial focusing) with translational applications (cell encapsulation, tissue scaffolds, drug delivery). Recent work (2023-2025) increasingly targets injectable granular hydrogels, single-cell therapeutic delivery and sustainable carbon-sequestering living materials, demonstrating an evolution from microscale transport phenomena to macroscopic biomedical and environmental impact. Scientific Awards No named awards are listed in the supplied text. Advising & Coordination Roles As Graduate Coordinator for the Department of Chemical and Biomedical Engineering, Professor Oakey oversees graduate program development and student mentoring. While no individual students are named, his role implies active supervision of M.S. and Ph.D. advisees in chemical and biomedical engineering. Laboratory & Teams The Oakey Research Group operates from the Energy and Environmental Research Building (EERB 435A) at the University of Wyoming. The lab enjoys R1-level research infrastructure and collaborates broadly with the Wyoming INBRE network, the Molecular and Cellular Life Sciences Program, and the Materials Science and Engineering Program.
University Medical Center Hamburg-EppendorfGermany
Syed Hani Hassan Abidi is an Associate Professor at the Department of Biomedical Sciences , School of Medicine , Nazarbayev University , Kazakhstan. His research integrates virology , immunology , viral oncology , and bioinformatics , with a focus on HIV molecular epidemiology , viral evolution , and drug resistance . He has led international projects across Pakistan, Kenya, Afghanistan, and Kazakhstan, and is recognized for innovative teaching and MOOC development. Education: PhD in Virology and Immunology Research Interests: His laboratory employs bioinformatics (machine learning, AI), genomics , and proteomics to study HIV phylodynamics , viral co-infections , and oncogenic viruses like EBV in prostate cancer. He also explores microbiome-immunity interactions and designs antiviral drugs/vaccines . Recent Research Trends: His 2025 publications emphasize COVID-19 immunopathology , HIV/syphilis epidemiology in Pakistan , and particle physics contributions via ATLAS , showcasing interdisciplinary impact. Awards & Recognition: Outstanding Teachers Award (2019, Aga Khan University) Fellowship of Higher Education (UK, 2022) Teaching & Grants: He pioneered Pakistan’s first MOOC on Computer-Based Drug Discovery (2014) and received a 2022 SoTL grant for MOOC-based molecular biology education. His teaching integrates animations , films , and flipped classrooms . Collaborations & Labs: Leads projects on HIV drug resistance , HCV genomics in Kazakhstan , and AI-driven dementia diagnostics (Kazakh Brain Atlas). His lab collaborates with global institutions to advance viral disease surveillance and therapeutic innovation .
Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
